MedTrace Logo

Evaluation of Safety and Pharmacodynamics of OP0201 Compared to Placebo in Healthy Adults

NCT03828149 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2019-12-30

Study results available
· View outcomes & findings →

Summary

Evaluation of Safety and Pharmacodynamics of OP0201 Compared to Placebo in Healthy Adults

Conditions

  • Healthy Adults

Interventions

COMBINATION_PRODUCT

Drug:OP0201

Drug: OP0201

COMBINATION_PRODUCT

Drug: Placebo

Drug: Placebo

Sponsors & Collaborators

  • Novus Therapeutics, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-08
Primary Completion
2019-03-07
Completion
2019-03-07
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03828149 on ClinicalTrials.gov